Zimmer Biomet Holdings Stock News

Zimmer Biomet's (ZBH) recently completed the spin-off of the non-core dental and spine business is expected to prove strategic.

Zimmer Biomet's (ZBH) recently completed the spin-off of the non-core dental and spine business is expected to prove strategic.

SVB Leerink has decided to maintain its Outperform rating of Zimmer Biomet Holdings (NYSE:ZBH) and raise its price target from $135.00 to $140.00. Shares of Zimmer Biomet Holdings are trading up 0.82%

Within the last quarter, Zimmer Biomet Holdings (NYSE:ZBH) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 3 5 1 0

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.

Zimmer Biomet Holdings Inc's (NYSE: ZBH) Q1 sales increased by 3.9% Y/Y to $1.66 billion (up 6.8% on a constant currency basis), beating the consensus of $1.59 billion. Adjusted EPS was $1.61, whic

Zimmer Biomet Holdings Inc Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Bryan Hanson – Chairman, President, and Chief Executive Officer Suky Upadhyay – Executive Vi

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.

Zimmer (ZBH) delivered earnings and revenue surprises of 15% and 4.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zimmer (ZBH) delivered earnings and revenue surprises of 15% and 4.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

DENTSPLY SIRONA's (XRAY) first-quarter results are likely to reflect strong performance at Technologies & Equipment business.

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.